Senate Files

Bills

S. 1302 119th Congress

Increasing Transparency in Generic Drug Applications Act

Latest action, Apr 3, 2025: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

How the Senate voted

The Senate hasn't taken a roll call on this bill in the Congresses covered.

6 cosponsors

Sponsored by Margaret Wood Hassan (Democrat). Cosponsors by party, House members included:

  • Democrats
  • Republicans
  • Independents
Cosponsors
2 D · 4 R
  • Democrat
  • Republican
  • Independent
6 senators cosponsoring

Referred to: Senate: Health, Education, Labor, and Pensions Committee

Who lobbied on it

Clients whose quarterly lobbying reports named it, each quarter.

18 clientsQ1 2025Q3 2026

The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.

COLLEGE OF AMERICAN PATHOLOGISTS
7 reports
VIATRIS (MYLAN, INC)
S-3 GROUP
7 reports
ASSOCIATION FOR ACCESSIBLE MEDICINES
6 reports
VIATRIS INC
HOLLAND & KNIGHT LLP
6 reports
ASSOCIATION OF ACCESSIBLE MEDICINES
MEHLMAN CONSULTING, INC.
5 reports
BCBSM INC
5 reports
BLUE CROSS AND BLUE SHIELD ASSOCIATION
5 reports
BLUE CROSS AND BLUE SHIELD OF FLORIDA INC
5 reports
BLUE CROSS BLUE SHIELD OF MICHIGAN
5 reports
GUIDEWELL MUTUAL HOLDING CORPORATION
5 reports
VIATRIS INC
5 reports
ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)
FIERCE GOVERNMENT RELATIONS
4 reports
BIOTECHNOLOGY INNOVATION ORGANIZATION
3 reports
BLUE CROSS AND BLUE SHIELD OF KANSAS INC
3 reports
GSK (FKA GLAXOSMITHKLINE INC.)
3 reports
All 25 of 29 clients
ClientLobbying firmReportsReports totalingFromToSenate
COLLEGE OF AMERICAN PATHOLOGISTS7$1.3MQ1 2025Q3 2026yes
VIATRIS (MYLAN, INC)S-3 GROUP7$420KQ1 2025Q3 2026yes
ASSOCIATION FOR ACCESSIBLE MEDICINES6$4.7MQ1 2025Q3 2026yes
VIATRIS INCHOLLAND & KNIGHT LLP6$0Q4 2025Q3 2026yes
ASSOCIATION OF ACCESSIBLE MEDICINESMEHLMAN CONSULTING, INC.5$300KQ4 2025Q3 2026yes
BCBSM INC5$148KQ4 2025Q3 2026yes
BLUE CROSS AND BLUE SHIELD ASSOCIATION5$6.3MQ4 2025Q3 2026yes
BLUE CROSS AND BLUE SHIELD OF FLORIDA INC5$480KQ4 2025Q3 2026yes
BLUE CROSS BLUE SHIELD OF MICHIGAN5$1.4MQ4 2025Q3 2026yes
GUIDEWELL MUTUAL HOLDING CORPORATION5$30KQ4 2025Q3 2026yes
VIATRIS INC5$2.8MQ1 2025Q1 2026yes
ASSOCIATION OF ACCESSIBLE MEDICINES (FORMERLY KNOWN AS GPHA)FIERCE GOVERNMENT RELATIONS4$240KQ1 2025Q3 2025yes
BIOTECHNOLOGY INNOVATION ORGANIZATION3$5.5MQ4 2025Q2 2026yes
BLUE CROSS AND BLUE SHIELD OF KANSAS INC3$30KQ1 2026Q3 2026yes
GSK (FKA GLAXOSMITHKLINE INC.)3$4.0MQ4 2025Q3 2025yes
NATIONAL AIR TRAFFIC CONTROLLERS ASSOCIATION3$1.2MQ1 2025Q3 2025yes
AMERICAN SOCIETY OF ANESTHESIOLOGISTS2$520KQ1 2025Q2 2025yes
APOTEX CORP.2$570KQ4 2025Q3 2025yes
ATLANTICAREWASHINGTON STRATEGIC CONSULTING2$40KQ1 2025Q2 2025yes
MASSACHUSETTS MEDICAL SOCIETY2$130KQ1 2025Q2 2025yes
PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION2$7.5MQ1 2025Q2 2025yes
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INCCOVINGTON & BURLING LLP2$0Q4 2025Q2 2025yes
ST. JOSEPHS REGIONAL MEDICAL CENTERWASHINGTON STRATEGIC CONSULTING2$40KQ1 2025Q2 2025yes
THE CAMPAIGN FOR SUSTAINABLE RX PRICINGMEHLMAN CONSULTING, INC.2$180KQ1 2025Q2 2025yes
VALLEY HEALTH SYSTEMWASHINGTON STRATEGIC CONSULTING2$40KQ1 2025Q2 2025yes